CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The ablation of pulmonary veins is a very effective treatment for the treatment of paroxysmal
atrial fibrillation. The benefit of the isolation of pulmonary veins in persistent atrial
fibrillation seems to be minor and the level of scientific evidence available requires
additional clinical trials to define the value of ablation in this type of patients.
The symptomatology of atrial fibrillation recurrences is variable among patients and among
differens moments in the same patient. Pharmacological treatment and ablation have been used
to reduce the symptomatology of atrial fibrillation recurrences and to increase the
proportion of asymptomatic recurrences. Different forms of electrical monitoring of the heart
rate are used to evaluate the effectiveness of an intervention. Frequents monitoring periods
provide the information of the heart rate and the effect of any intervention.
The "Confirm RX heart monitor® (Abbott)" is a subcutaneous implantable device that provides
continuous monitoring of the heart rate for more than 3 years without any effect on cardiac
function. This implantable Holter automatically detects and saves atrial and ventricular
arrhythmic episodes. The device can be analyzed in person or remotely, and can help to make
decisions regarding anticoagulant and antiarrhythmic treatment of patients, while
representing a powerful research tool for evaluate the effectiveness of different therapeutic
options.
This is a prospective, randomized, multicenter study that compares the relative efficacy and
safety of cryoablation of pulmonary veins using the Arctic Front Advance® balloon catheter
with antiarrhythmic treatment in patients with persistent atrial fibrilation.